Sonnet BioTherapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own1.30% Shs Outstand63.91M Perf Week-5.00%
Market Cap17.00M Forward P/E- EPS next Y-0.40 Insider Trans0.00% Shs Float58.66M Perf Month4.35%
Income-27.50M PEG- EPS next Q-0.10 Inst Own9.90% Short Float3.63% Perf Quarter-29.26%
Sales0.70M P/S24.29 EPS this Y85.40% Inst Trans45.38% Short Ratio1.05 Perf Half Y-37.04%
Book/sh0.14 P/B1.90 EPS next Y15.20% ROA-152.70% Target Price2.25 Perf Year-83.06%
Cash/sh0.21 P/C1.25 EPS next 5Y- ROE-226.40% 52W Range0.23 - 2.07 Perf YTD-35.61%
Dividend- P/FCF- EPS past 5Y54.30% ROI- 52W High-87.15% Beta0.59
Dividend %- Quick Ratio2.30 Sales past 5Y-59.00% Gross Margin- 52W Low16.67% ATR0.02
Employees9 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)48.92 Volatility7.49% 8.92%
OptionableNo Debt/Eq0.00 EPS Q/Q57.70% Profit Margin- Rel Volume0.20 Prev Close0.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.03M Price0.27
Recom1.50 SMA201.66% SMA50-2.49% SMA200-36.59% Volume410,769 Change-5.00%
Jun-09-22 07:00AM  
Jun-02-22 09:25AM  
May-10-22 08:15AM  
Apr-13-22 07:00AM  
Apr-08-22 01:05PM  
Mar-16-22 07:00AM  
Feb-09-22 06:30AM  
Feb-08-22 07:00AM  
Dec-20-21 12:58PM  
Dec-17-21 06:30AM  
Aug-30-21 04:01PM  
Aug-19-21 09:35PM  
Aug-16-21 06:30AM  
Jun-14-21 07:45AM  
Jun-08-21 04:30PM  
May-17-21 07:00AM  
May-10-21 06:30AM  
May-03-21 06:00AM  
Mar-29-21 04:30PM  
Mar-22-21 07:00AM  
Feb-16-21 08:10AM  
Feb-03-21 06:30AM  
Feb-01-21 06:30AM  
Jan-25-21 06:30AM  
Dec-17-20 06:30AM  
Nov-30-20 08:30AM  
Sep-01-20 08:30AM  
Aug-25-20 07:30AM  
Aug-24-20 07:37AM  
Aug-14-20 07:30AM  
Aug-04-20 07:35AM  
Jul-20-20 07:30AM  
Jul-15-20 07:30AM  
May-18-20 07:30AM  
Apr-06-20 07:30AM  
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.